TY  - CONF

T1  - Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial

JO  - JOURNAL OF INVESTIGATIVE DERMATOLOGY

PY  - 2021/01/01

AU  - Paller A

AU  - Cork MJ

AU  - Marcoux D

AU  - Zhang H

AU  - Chuang C

AU  - Zhang A

AU  - Chao J

ED  - 

VL  - 141

IS  - 5

SP  - S84

EP  - S84

Y2  - 2024/12/22

ER  -